MedPath
Found 1 clinical trials|View Analysis
Sort by:

Study to Assess the Efficacy and Safety of NBI-1065845 in Adults With Major Depressive Disorder (MDD)

Phase 2
Completed
Conditions
Major Depressive Disorder
Interventions
Drug: Placebo
Drug: NBI-1065845
First Posted Date
2022-01-24
Last Posted Date
2024-03-25
Lead Sponsor
Neurocrine Biosciences
Target Recruit Count
183
Registration Number
NCT05203341
Locations
🇸🇪

Neurocrine Clinical Site, Stockholm, Sweden

© Copyright 2025. All Rights Reserved by MedPath